CLINICAL RESEARCH: ATRIAL FIBRILLATION/FLUTTER, TACHYCARDIA
Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation
Koichiro Kumagai, MD*,*,
Hideko Nakashima, MD*,
Hidenori Urata, MD*,
Naoki Gondo, MD*,
Kikuo Arakawa, MD, FACC* and
Keijiro Saku, MD, FACC*
* Department of Cardiology, School of Medicine, Fukuoka University, Fukuoka, Japan
Manuscript received July 26, 2002;
revised manuscript received November 15, 2002,
accepted December 26, 2002.
* Reprint requests and correspondence: Dr. Koichiro Kumagai, Department of Cardiology, School of Medicine, Fukuoka University, 7-45-1, Nanakuma, Jonan-ku, Fukuoka, 814-0180 Japan.
kxk{at}fukuoka-u.ac.jp
 |
Abstract
|
|---|
OBJECTIVES: The purpose of the present study was to evaluate the effect of angiotensin II type 1 receptor (AT1R) antagonist on chronic structural remodeling in atrial fibrillation (AF).
BACKGROUND: We previously reported that an AT1R antagonist, candesartan, prevents acute electrical remodeling in a rapid pacing model. However, the effect of candesartan on chronic structural remodeling in AF is unclear.
METHODS: Sustained AF was induced in 20 dogs (10 in a control group and 10 in a candesartan group) by rapid pacing of the right atrium (RA) at 400 beats/min for five weeks. Candesartan was administered orally (10 mg/kg/day) for one week before rapid pacing and was continued for five weeks. The AF duration, atrial effective refractory period (AERP) at four sites in the RA, and intra-atrial conduction time (CT) from the RA appendage to the other three sites were measured every week.
RESULTS: The mean AF duration in the control group after five weeks was significantly longer than that with candesartan (1,333 ± 725 vs. 411 ± 301 s, p < 0.01). The degree of AERP shortening after five weeks was not significantly different between the two groups. The CT from the RA appendage to the low RA after five weeks with candesartan was significantly shorter than that in the control (43 ± 14 vs. 68 ± 10 ms, p < 0.05). The candesartan group had a significantly lower percentage of interstitial fibrosis than the control group (7 ± 2% vs. 16 ± 1% at the RA appendage, p < 0.001).
CONCLUSIONS: Candesartan can prevent the promotion of AF by suppressing the development of structural remodeling.
|
Abbreviations and Acronyms
| | ACE | = angiotensin-converting enzyme | | AERP | = atrial effective refractory period | | AF | = atrial fibrillation | | Ang II | = angiotensin II | | AT1R | = angiotensin II type 1 receptor | | CT | = conduction time | | Erk | = extracellular signal-regulated kinases |
|
Several studies have shown that activation of the renin-angiotensin system is associated with the mechanism of atrial fibrillation (AF) (1–3). We previously reported that the blockade of angiotensin II (Ang II) prevented the electrical remodeling induced by short-term rapid atrial pacing (4). However, the effects of these drugs on long-term atrial electrophysiologic and structural remodeling are still unclear. Goette et al. (1) observed that the activation of angiotensin-converting enzyme (ACE)-dependent extracellular signal-regulated kinases (Erk1/Erk2) was involved in the mechanism of the development of atrial fibrosis in patients with AF. They also showed the down-regulation of atrial angiotensin II type 1 receptor (AT1R) and the up-regulation of AT2R in AF patients (2). It is well known that architectural alterations of the atria, including atrial dilation and tissue fibrosis, are associated with atrial dysfunction (5,6). Li et al. (6) reported that electrical heterogeneity probably due to atrial fibrosis might play a critical role in the induction and promotion of AF in an arrhythmogenic substrate in the canine heart failure model. Considering previous observations, we hypothesized that structural abnormalities caused by an activated renin-angiotensin system during chronic atrial activation might participate in the mechanisms of AF maintenance.
The purpose of this study was to investigate the effects of the blockade of Ang II on long-term atrial remodeling in the canine rapid pacing model.
|
Methods
|
|---|
Animal preparation.
All experiments were performed in accordance with the guidelines specified by the Institutional Animal Care and Use Committee, the American Heart Association Policy on Research Animal Use, and the Public Health Service Policy on the Use of Laboratory Animals.
Twenty mongrel dogs of either gender, weighing 12 to 25 kg, were randomly divided into two groups. In the candesartan group (n = 10), oral administration of candesartan (10 mg/kg/day) was started one week before the baseline study and was continued to the end of the study. The dogs in the control group (n = 10) did not receive candesartan.
All dogs were anesthetized with an intravenous injection of pentobarbital (25 mg/kg), and, after intubation and mechanical ventilation, anesthesia was maintained with halothane. A tachy-pacing generator (Medtronic, Minneapolis, Minnesota) was implanted in a subcutaneous pocket in the neck and attached to a pacing lead in the right atrial appendage. The chest was opened through the right fourth intercostal space, and four electrodes pair were sutured to four sites in the right atrium (appendage, and high lateral, low lateral, and anterior wall). At the completion of surgery, the dogs were given antibiotics and then allowed to recover. Postoperative care included the administration of antibiotics and analgesics.
Baseline electrophysiologic study.
One week after the operation, the dogs were reanesthetized with pentobarbital (25 mg/kg) and ventilated by halothane. The arterial blood gases were adjusted to between pH 7.35 and 7.45 during ventilation. The surface electrocardiogram lead II, intracardiac electrograms, and blood pressure were continuously monitored and recorded during the experiment. The pulmonary capillary wedge pressure, the pulmonary artery pressure, and the right atrial pressure were measured using a Swan-Ganz catheter.
Atrial effective refractory periods (AERPs) at four sites were measured at three basic cycle lengths (200, 300, 400 ms). Five basic drive stimuli were followed by a single premature stimulus, and all stimuli were twice the diastolic threshold. The S1-S2 interval was increased in steps of 2 ms, and AERP was determined to be the shortest S1-S2 interval that resulted in a propagated atrial response. The AERP dispersion was measured as the difference between maximum and minimum AERP among four sites. Intra-atrial conduction times (CT) from the appendage to the other three sites (high lateral, low lateral and anterior wall) were measured during appendage pacing at each basic cycle length.
Atrial fibrillation was defined as a rapid, irregular atrial rhythm with varying atrial electrogram morphology. The inducibility of AF was assessed by premature atrial stimulation during AERP measurement and atrial burst pacing (10 Hz for 1 to 10 s). If induced AF persisted >30 min, electrical cardioversion was performed. To estimate the mean AF duration, AF was induced 30 times if the AF duration was <10 min and 5 times if AF lasted between 10 and 15 min. When electrocardioversion was applied, AF induction was repeated after the 15-min rest period.
Electrophysiologic study after rapid atrial pacing.
After the measurement of baseline electrophysiologic and hemodynamic parameters, programmed atrial pacing at 400 beats/min using 2-ms pulses at twice the threshold current was started and continued for five weeks in both the control and candesartan groups. The tachy-pacing generator was turned off every week to allow for repeated assessment by an electrophysiologic study.
Histology.
At the end of the experiments, the heart was quickly removed and weighed. To investigate the influence of rapid pacing on pathologic properties, the atrial tissues of five sham dogs without rapid atrial pacing were observed in the same operation. The tissues of the left and right atrial free wall and appendages were cut into small blocks about 10 x 5 mm and immersed in 10% phosphate-buffered formalin for 24 h. After dehydration, each section was cut in 4-µm-thick slices. Deparaffinized sections were stained with hematoxylin-eosin and Masson’s trichrome. Microscopic images were scanned into a personal computer with Photoshop. Image files were analyzed with National Institutes of Health software (NIH image 1.61). Connective tissue was differentiated on the basis of its color and expressed as a percentage of the reference tissue area.
Statistical analysis.
All values are expressed as mean ± SD. Continuous values were compared with analysis of variance. A paired t test was used to evaluate differences between groups of discrete variables. A value of p < 0.05 was considered statistically significant.
|
Results
|
|---|
Hemodynamic changes.
The hemodynamic data are provided in Table 1. Although the blood pressure was not significantly different between the control and candesartan groups throughout the experiment, the pulmonary capillary wedge pressure, mean pulmonary artery pressure, and mean right atrial pressure in the candesartan group were significantly less than those in the control group.
Changes of electrophysiologic properties.
In both the control and candesartan groups, AERP shortening was most pronounced after one week of rapid pacing and continued during pacing (Table 2, Fig. 1). The degree of AERP shortening after rapid pacing was not significantly different between the two groups (Table 2, Fig. 1). Furthermore, the physiologic rate adaptation of the AERP, which was observed before the rapid pacing, was attenuated after five weeks of pacing in both groups (Table 2). There was no significant difference in the dispersion of AERP after five weeks between the two groups (control group vs. candesartan group: 14 ± 12 vs. 13 ± 13 ms, 9 ± 10 vs. 8 ± 8 ms, and 10 ± 9 vs. 8 ± 10 ms at the basic cycle length of 200, 300, and 400 ms, respectively).
View larger version (18K):
[in this window]
[in a new window]
|
Figure 1 Time course of the percent changes in the atrial effective refractory period (AERP) of the right atrial appendage and intra-atrial conduction time (CT) from the right atrial appendage to the lower right atrial wall at a basic cycle length of 300 ms, and the mean duration of induced atrial fibrillation (AF) in the control (white circles, white bars) and candesartan (black circles, black bars) groups. The degree of AERP shortening was similar between the two groups, the intra-atrial CT in the candesartan group was significantly shorter than that in the control group, and the mean AF duration in the candesartan group was significantly shorter than that in the control group.  p < 0.01, *p < 0.05 compared with the control group.
|
|
Although the baseline intra-atrial CT was not different between the control and candesartan groups (Table 3), in the control group, the CT from the right atrial appendage to the other three sites gradually prolonged and the value after five weeks of pacing was significantly longer than that in the candesartan group (Table 3, Fig. 1). On the other hand, CT in the candesartan group was not significantly prolonged throughout the study (Table 3, Fig. 1).
In the baseline, AF lasting more than 30 s was not induced in both the control and candesartan groups (control group: 11 ± 9 s; candesartan group: 12 ± 10 s) (Fig. 1). Rapid pacing caused a significant increase in the AF duration in both groups compared with the baseline (Fig. 1). When the pacemaker was turned off, there were no dogs with AF. Some episodes of AF were induced with a single extra stimulus in two dogs in the control group and one dog in the candesartan group; however, in other dogs AF was induced with burst pacing. Sustained AF (>900 s) was induced in 7 of 10 control dogs and electrical cardioversion was performed in all 7 dogs, whereas it was not induced at all in the candesartan group, and the mean duration of induced AF in the candesartan group was significantly shorter than that in the control group (control group vs. candesartan group: 1,333 ± 725 vs. 411 ± 301 s after 5 weeks, p < 0.01) (Fig. 1).
There was no significant difference in the mean AF cycle lengths (control group vs. candesartan group: 89 ± 19 vs. 95 ± 11 ms after 5 weeks) and the mean ventricular rate during rapid atrial pacing (control group vs. candesartan group: 212 ± 13 vs. 209 ± 10 beats/min after 5 weeks) between the two groups.
Pathologic examination.
Histologic studies were performed to identify the potential pathologic substrate underlying conduction abnormalities in rapid-pacing dogs. Pericardial inflammation, effusion, and hemorrhage were not observed in any of the dogs. Representative histologic sections from each group are shown in Figure 2. Atrial myocyte from sham dogs showed a normal composition of sarcomeres distributed throughout the cell, and the intracellular space also appeared normal. In contrast, atrial myocytes of control dogs showed a loss of some contractile materials and abnormal sarcomeres. In addition, extensive interstitial fibrosis, evidenced by Masson trichrome stain was found in these tissues. Thick layers of fibrous tissue were observed in the endocardium and epicardium. Furthermore, the amount of connective tissue was increased, and this extended around parenchymal cells. In contrast, these pathologic abnormalities of atrial tissues were attenuated in the candesartan group.
View larger version (74K):
[in this window]
[in a new window]
|
Figure 2 Representative histologic sections of the right atrial free wall from each group (Masson trichrome stain) from a sham dog (A), a fifth week rapid pacing dog (B), and a fifth week rapid pacing with candesartan treated dog (C). In the sham dog, the intracellular space appeared normal. In the control dog, extensive interstitial fibrosis, evidenced by Masson trichrome stain, was found. In the candesartan treated dog, interstitial fibrosis was attenuated. Magnification: x400.
|
|
A quantitative analysis of fibrosis is shown in Figure 3. The percentage of fibrosis in all atrial regions in the candesartan group was markedly lower than that in the control group (7 ± 2% vs. 16 ± 1% at the right atrial appendage, p < 0.001), although greater than that in the sham group (7 ± 2% vs. 4 ± 1% at the right atrial appendage, p < 0.05). Because the rapid pacing lead was fixed to the right atrial appendage, these histologic changes seemed to be slightly greater in the right atria than in the left atria. However, this difference was not significant.
View larger version (23K):
[in this window]
[in a new window]
|
Figure 3 The percentage of fibrosis of the free walls and appendages in both atria after five weeks of pacing. The percentage of fibrosis in all atrial regions in the candesartan group was markedly lower than that in the control, although greater than that in the sham group. Hatched bars = sham group; white bars = control group; black bars = candesartan group.  p < 0.001 compared with the control group. *p < 0.05 compared with the sham group. RAA = right atrial appendage; RAFW = right atrial free wall; LAA = left atrial appendage; LAFW = left atrial free wall.
|
|
|
Discussion
|
|---|
Main findings.
This study has demonstrated for the first time that Ang II contributes to the development of AF in a long-term rapid pacing model. The major findings of this study are as follows: 1) the degree of AERP shortening and the dispersion of AERP after five weeks were similar between the control group and the candesartan group; 2) the intra-atrial CT in the candesartan group was significantly shorter than that in the control group; 3) candesartan significantly reduced the percentage of interstitial fibrosis compared with that in the control group; and 4) the mean AF duration in the candesartan group was significantly shorter than that in the control group. These findings indicate that Ang II may be involved in structural remodeling in the mechanism of chronic AF.
Possible mechanisms of AF promotion.
Previous studies have shown that shortened AERP and loss of its adaptation to rate, which have been referred to as electrical remodeling, are observed in the pacing-induced AF model (7–9). Wijffels et al. (10) reported AERP shortening and increased vulnerability to AF in the instrumented goat model. However, there was a discrepancy in the time course between these two changes. The AERP shortening began within 24 h, whereas AF started to get stable only after more than a week, and this lasted for a long time. These results indicated that a decreased wavelength, which is caused by a shortened AERP and decreased conduction velocity, might play a critical role in the development of chronic AF. Furthermore, Everett et al. (11) demonstrated that a shortened AERP returned to the baseline level in 7 to 14 days after six weeks of rapid atrial pacing. Despite the complete normalization of AERP, the structural abnormalities of the atria persisted. Based on these results, not only AERP shortening but also other additional factors, including functional and structural abnormalities of the atria, may be involved in the promotion of AF.
In the present study, AERP was significantly shortened in the first week, and there was no further shortening of the AERP with pacing. On the other hand, the intra-atrial CT was gradually prolonged, and after five weeks of rapid pacing it was significantly longer than the baseline value. Furthermore, the inducibility of AF and its mean duration tended to increase and run parallel to the intra-atrial conduction slowing, and significant differences were seen after the fourth and fifth weeks compared with that after the first week. These findings indicate that conduction slowing may be related to heterogeneous conduction abnormalities, which may contribute to the initiation and maintenance of AF.
Electrical remodeling and the renin-angiotensin system.
Previous studies have shown that atrial tachycardia–induced electrical remodeling, which consisted of AERP shortening and loss of physiologic rate adaptation, increased the inducibility and stability of AF (7–10). The intracellular calcium overload during high-frequency atrial activation is thought to contribute to this phenomenon of electrical remodeling (8,9,12,13). Accordingly, an L-type calcium channel blocker, verapamil, has been suggested to prevent short-term electrical remodeling in animal and human studies (8,9,12,13). However, several studies have demonstrated that verapamil could not prevent long-term tachycardia-induced AERP shortening and maladaptation of AERP, and rather than reducing the inducibility of AF, it increased the duration of induced AF (14–17). In addition, we have previously reported that verapamil increased intra-atrial conduction delay and fragmented activity in patients with paroxysmal AF (18). These results suggested that intracellular calcium overload might contribute to a mechanism of electrical remodeling only in the short term, but not in the long term.
We previously reported that ACE inhibitor and AT1R antagonist prevented AERP shortening in a canine short-term rapid pacing model (4). The beneficial effects of these drugs may be due to, besides the prevention of intracellular calcium overload, decreased atrial stretching during rapid atrial activation. In the present study, we examined the effects of an AT1R antagonist, candesartan, on long-term atrial electrophysiologic and structural remodeling. Candesartan did not prevent AERP shortening after one week of rapid pacing, suggesting that only prevention of calcium overload cannot prevent long-term electrical remodeling. Shinagawa et al. (19) also reported that the ACE inhibitor enalapril did not prevent AERP shortening after seven days of rapid pacing, suggesting apparent mechanical differences between short-term remodeling and long-term remodeling. They described that short-term remodeling is primarily caused by functional changes such as Cai2+- and voltage-dependent L-type Ca current inactivation, whereas long-term remodeling is caused by changes in ion channel expression due to reduced levels of messenger ribonucleic acid encoding ion channel subunits and possibly post-transcriptional mechanisms as well. This may explain why candesartan inhibited short-term electrical remodeling but not long-term electrical remodeling. However, candesartan significantly decreased the inducibility and the duration of AF after five weeks of rapid atrial pacing, probably by preventing the development of conduction slowing. Therefore, the blockade of Ang II may attenuate the arrhythmogenic substrate, which may promote the transition to chronic AF.
Structural remodeling and the renin-angiotensin system.
Atrial fibrillation is associated with progressive structural changes of the atria, resulting in atrial dilation and increased interstitial fibrosis (5,11). Li et al. (6) reported that decreased AERP and increased AERP heterogeneity were not observed in a heart-failure dog model, whereas AF inducibility and the duration of the induced AF were significantly increased compared with those in control dogs. Local conduction slowing, its heterogeneity, and the percentage of interstitial fibrosis of the atria were prominent in dogs with heart failure. Therefore, the changes in local atrial conduction properties caused by interstitial fibrosis favor the maintenance of AF in dogs with heart failure. Although rapid atrial pacing was performed without creating atrio-ventricular block, the ventricular rate in the present study was faster than 200 beats/min, which provides similar effects to the previously reported ventricular pacing heart-failure model, as reflected in our data on hemodynamic changes.
Recently, Goette et al. (1) demonstrated that the expression of ACE and Erk1/Erk2 were increased in patients with AF. Willems et al. (20) established that the development of AF by rapid pacing was associated with an increase in plasma level of Ang II in a sheep model. In animal studies, it has been reported that high atrial pressure directly caused AERP shortening and increased AERP dispersion, resulting in increased vulnerability to AF (21–23). In addition to these direct effects on electrophysiologic properties, increased atrial stretching activates the Erk cascade through the AT1R, which may induce interstitial fibrosis of the atria (1,24). More interestingly, treatment with ACE inhibitor decreased the level of an activated Erk1/Erk2. Although we did not measure these intracellular signaling kinases, AT1R antagonist may also have similar inhibitory effects on these kinases, resulting in decreasing atrial fibrosis. The inhibition of local Ang II can prevent the promotion of AF by suppressing the development of arrhythmogenic structural substrate. In addition, AT1R antagonist has been reported to decrease atrial pressure (25). Therefore, it is possible that a decrease in atrial stretching by candesartan may directly precipitate electrophysiologic changes to prevent AF.
Study limitations.
Electrophysiologic measurements were made only in the right atrium, not in the left atrium because to suture electrodes on the left atrial free wall we have to hold up the heart, and this made the heart bent, resulting in dramatically decreased blood pressure and heart rate. Therefore, electrophysiologic characteristics in the left atrium are still unknown.
Angiotensin-converting enzyme inhibitor and AT1R antagonist have each been shown to have beneficial effects on ventricular remodeling after myocardial infarction (26,27). Furthermore, we previously demonstrated that both ACE inhibitor and AT1R antagonist could prevent short-term electrical remodeling in a canine rapid atrial pacing model (4). In the present study, we did not test the effect of ACE inhibitor on long-term remodeling. Therefore, the results of the present study did not provide an answer whether ACE inhibitor was also effective to prevent long-term atrial remodeling. However, our preliminary analysis using dog atrial homogenate suggested that ACE and chymase almost equally contributed to atrial Ang II formation, because approximately 40% of total atrial Ang II formation was due to ACE, whereas the rest was due to chymase (H. Nakashima, MD, et al., unpublished observations, 2002). This fact may indicate that ACE inhibitor is also effective as AT1R antagonist in dog. In fact, the beneficial effect of ACE inhibitor in atrial structural remodeling was shown by Li et al. (28) and Shi et al. (29). Further biochemical analysis is necessary to determine the contribution rate of both enzymes in atrial tissue Ang II formation after long-term pacing.
It is still unclear whether the beneficial effects of AT1R antagonist on long-term remodeling are due to the improvement of systemic conditions or the blockade of local Ang II in the atria. In addition, although it is possible that the density and affinity of Ang II receptor are different in each part of the atria, the density and affinity of AT1R/AT2R and the activities of ACE and Erk1/Erk2 were not measured. Thus, further experiments will be needed to evaluate the detailed mechanisms of preventive effects of AT1R antagonist on AF.
Clinical implications.
Previous studies have shown that several antiarrhythmic drugs are effective for preventing short-term electrical remodeling of AF (8,9,12,13,30–32). However, the effects of these drugs on long-term atrial remodeling, including electrophysiologic and structural changes, are still controversial. Atrial fibrillation is a common arrhythmia in patients with heart failure (6,33), and we often experience difficulties in controlling drug-induced negative inotropic and proarrhythmic effects, especially in patients with left ventricular dysfunction. Van Den Berg et al. (34) showed that an ACE inhibitor, lisinopril, decreased the recurrence of AF after cardioversion in patients with congestive heart failure. Recently, Pedersen et al. (3) observed that an ACE inhibitor, trandolapril, reduced the incidence of AF in patients with left ventricular dysfunction after myocardial infarction. In the present study, we showed that an AT1R antagonist could prevent the structural remodeling that promotes AF in a canine pacing model. However, the main Ang II-forming enzyme in the human atria is chymase, but not ACE (chymase:ACE=21:1) (35), suggesting that AT1R antagonist may have more beneficial effects than ACE inhibitor in human atria. Thus, these results suggest that AT1R antagonist may constitute a novel therapeutic approach to preventing AF.
|
Footnotes
|
|---|
Supported in part by Grant 11670725 from the Science Research Fund of Ministry of Education, Science and Culture, Japan.
|
References
|
|---|
1. Goette A, Staack T, Rocken C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol. 2000;35:1669–1677[Abstract/Free Full Text]
2. Goette A, Arndt M, Rocken C, et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation. 2000;101:2678–2681[Abstract/Free Full Text]
3. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999;100:376–380[Abstract/Free Full Text]
4. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation. 2000;101:2612–2617[Abstract/Free Full Text]
5. Ausma J, Wijffels M, Thone F, Wouters L, Allessie M, Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation. 1997;96:3157–3163[Abstract/Free Full Text]
6. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation. 1999;100:87–95[Abstract/Free Full Text]
7. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation. 1995;92:1954–1968[Abstract/Free Full Text]
8. Goette A, Honeycutt C, Langberg JJ. Electrical remodeling in atrial fibrillation: time course and mechanisms. Circulation. 1996;94:2968–2974[Abstract/Free Full Text]
9. Tieleman RG, De Langen C, Van Gelder IC, et al. Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation. 1997;95:1945–1953[Abstract/Free Full Text]
10. Wijffels MC, Kirchhof CJ, Dorland R, Power J, Allessie MA. Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats: roles of neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation. Circulation. 1997;96:3710–3720[Abstract/Free Full Text]
11. Everett TH, Li H, Mangrum JM, et al. Electrical, morphological, and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation. Circulation. 2000;102:1454–1460[Abstract/Free Full Text]
12. Tieleman RG, Van Gelder IC, Crijns HJ, et al. Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol. 1998;31:167–173[Abstract/Free Full Text]
13. Daoud EG, Knight BP, Weiss R, et al. Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Circulation. 1997;96:1542–1550[Abstract/Free Full Text]
14. Shenasa M, Kus T, Fromer M, LeBlanc RA, Dubuc M, Nadeau R. Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation. Am J Cardiol. 1988;62:403–407[CrossRef][Medline]
15. Lee SH, Yu WC, Cheng JJ, et al. Effect of verapamil on long-term tachycardia-induced atrial electrical remodeling. Circulation. 2000;101:200–206[Abstract/Free Full Text]
16. Fareh S, Benardeau A, Thibault B, Nattel S. The T-type Ca(2+) channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling in dogs. Circulation. 1999;100:2191–2197[Abstract/Free Full Text]
17. Ramanna H, Elvan A, Wittkampf FH, de Bakker JM, Hauer RN, Robles de Medina EO. Increased dispersion and shortened refractoriness caused by verapamil in chronic atrial fibrillation. J Am Coll Cardiol. 2001;37:1403–1407[Abstract/Free Full Text]
18. Kumagai K, Matsuo K, Ono M, et al. Effects of verapamil on electrophysiological properties in paroxysmal atrial fibrillation. Pacing Clin Electrophysiol. 1993;16:309–316[CrossRef][Medline]
19. Shinagawa K, Mitamura H, Ogawa S, Nattel S. Effects of inhibiting Na(+)/H(+)-exchange or angiotensin converting enzyme on atrial tachycardia-induced remodeling. Cardiovasc Res. 2002;54:438–446[Abstract/Free Full Text]
20. Willems R, Sipido KR, Holemans P, Ector H, Van de Werf F, Heidbuchel H. Different patterns of angiotensin II and atrial natriuretic peptide secretion in a sheep model of atrial fibrillation. J Cardiovasc Electrophysiol. 2001;12:1387–1392[CrossRef][Medline]
21. Sideris DA, Toumanidis ST, Tselepatiotis E, et al. Atrial pressure and experimental atrial fibrillation. Pacing Clin Electrophysiol. 1995;18:1679–1685[Medline]
22. Satoh T, Zipes DP. Unequal atrial stretch in dogs increases dispersion of refractoriness conducive to developing atrial fibrillation. J Cardiovasc Electrophysiol. 1996;7:833–842[Medline]
23. Ravelli F, Allessie M. Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation. 1997;96:1686–1695[Abstract/Free Full Text]
24. Kijima K, Matsubara H, Murasawa S, et al. Mechanical stretch induces enhanced expression of angiotensin II receptor subtypes in neonatal rat cardiac myocytes. Circ Res. 1996;79:887–897[Abstract/Free Full Text]
25. Gottlieb SS, Dickstein K, Fleck E, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation. 1993;88:1602–1609[Abstract/Free Full Text]
26. Hu K, Gaudron P, Anders HJ, et al. Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin. Cardiovasc Res. 1998;39:401–412[Abstract/Free Full Text]
27. Harada K, Komuro I, Hayashi D, Sugaya T, Murakami K, Yazaki Y. Angiotensin II type 1a receptor is involved in the occurrence of reperfusion arrhythmias. Circulation. 1998;97:315–317[Abstract/Free Full Text]
28. Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation. 2001;104:2608–2614[Abstract/Free Full Text]
29. Shi Y, Li D, Tardif JC, Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res. 2002;54:456–461[Abstract/Free Full Text]
30. Fareh S, Benardeau A, Nattel S. Differential efficacy of L- and T-type calcium channel blockers in preventing tachycardia-induced atrial remodeling in dogs. Cardiovasc Res. 2001;49:762–770[Abstract/Free Full Text]
31. Chen YJ, Lee SH, Hsieh MH, et al. Effects of 17beta-estradiol on tachycardia-induced changes of atrial refractoriness and cisapride-induced ventricular arrhythmia. J Cardiovasc Electrophysiol. 1999;10:587–598[Medline]
32. Sticherling C, Oral H, Horrocks J, et al. Effects of digoxin on acute, atrial fibrillation-induced changes in atrial refractoriness. Circulation. 2000;102:2503–2508[Abstract/Free Full Text]
33. Murgatroyd FD, Camm AJ. Atrial arrhythmias. Lancet. 1993;341:1317–1322[CrossRef][Medline]
34. Van Den Berg MP, Crijns HJGM, Van Veldhuisen DJ, Nico G, De Kam PJ, Lie KI. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Fail. 1995;1:355–363[Medline]
35. Ihara M, Urata H, Shirai K, et al. High cardiac angiotensin-II-forming activity in infarcted and non-infarcted human myocardium. Cardiology. 2000;94:247–253[CrossRef][Medline]
This article has been cited by other articles:
|
|
|
|
 
F. Hegbom, A. Tveit, I. Grundvold, H. Arnesen, and P. Smith
Effects of angiotensin receptor blockade on serial P-wave signal-averaged electrocardiograms after electrical cardioversion of persistent atrial fibrillation
Europace,
October 1, 2009;
11(10):
1301 - 1307.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Smit, I. C. Van Gelder, H. Tomoda, M. Disertori, R. Latini, A. P. Maggioni, and the Gruppo Italiano per lo Studio della Sopravvive
Valsartan and Recurrent Atrial Fibrillation
N. Engl. J. Med.,
July 30, 2009;
361(5):
532 - 533.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Kirchhof, J. Bax, C. Blomstrom-Lundquist, H. Calkins, A. J. Camm, R. Cappato, F. Cosio, H. Crijns, H.-C. Diener, A. Goette, et al.
Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'
Europace,
July 1, 2009;
11(7):
860 - 885.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Crandall, D. J. Bradley, D. L. Packer, and S. J. Asirvatham
Contemporary Management of Atrial Fibrillation: Update on Anticoagulation and Invasive Management Strategies
Mayo Clin. Proc.,
July 1, 2009;
84(7):
643 - 662.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Kirchhof, J. Bax, C. Blomstrom-Lundquist, H. Calkins, A. John Camm, R. Cappato, F. Cosio, H. Crijns, H.-C. Diener, A. Goette, et al.
Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'
Eur. Heart J.,
June 17, 2009;
(2009)
ehp235v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
The GISSI-AF Investigators
Valsartan for Prevention of Recurrent Atrial Fibrillation
N. Engl. J. Med.,
April 16, 2009;
360(16):
1606 - 1617.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Camm, P. Kirchhof, G. Y.H. Lip, I. Savelieva, and S. Ernst
CHAPTER 29 Atrial Fibrillation
ESC Textbook of Cardiovascular Medicine,
January 1, 2009;
2(1):
med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Wachtell, R. B. Devereux, P. A. Lyle, P. M. Okin, and E. Gerdts
The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy
Therapeutic Advances in Cardiovascular Disease,
December 1, 2008;
2(6):
507 - 513.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Bollmann, A. Tveit, D. Husser, M. Stridh, L. Sornmo, P. Smith, and S. B. Olsson
Fibrillatory rate response to candesartan in persistent atrial fibrillation
Europace,
October 1, 2008;
10(10):
1138 - 1144.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Adam, H.-R. Neuberger, M. Bohm, and U. Laufs
Prevention of Atrial Fibrillation With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors
Circulation,
September 16, 2008;
118(12):
1285 - 1293.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Laszlo, C. Eick, N. Rueb, S. Weretka, H.-J. Weig, J. Schreieck, and R. F Bosch
Inhibition of the renin-angiotensin system: effects on tachycardia-induced early electrical remodelling in rabbit atrium
Journal of Renin-Angiotensin-Aldosterone System,
September 1, 2008;
9(3):
125 - 132.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. L. Serra and M. Bendersky
Review: Atrial fibrillation and renin-angiotensin system
Therapeutic Advances in Cardiovascular Disease,
June 1, 2008;
2(3):
215 - 223.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Nattel, B. Burstein, and D. Dobrev
Atrial Remodeling and Atrial Fibrillation: Mechanisms and Implications
Circ Arrhythm Electrophysiol,
April 1, 2008;
1(1):
62 - 73.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Burstein and S. Nattel
Atrial Fibrosis: Mechanisms and Clinical Relevance in Atrial Fibrillation
J. Am. Coll. Cardiol.,
February 26, 2008;
51(8):
802 - 809.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Goette and U. Lendeckel
Electrophysiological effects of angiotensin II. Part I: signal transduction and basic electrophysiological mechanisms
Europace,
February 1, 2008;
10(2):
238 - 241.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-T. Tsai, L.-P. Lai, K.-T. Kuo, J.-J. Hwang, C.-S. Hsieh, K.-L. Hsu, C.-D. Tseng, Y.-Z. Tseng, F.-T. Chiang, and J.-L. Lin
Angiotensin II Activates Signal Transducer and Activators of Transcription 3 via Rac1 in Atrial Myocytes and Fibroblasts: Implication for the Therapeutic Effect of Statin in Atrial Structural Remodeling
Circulation,
January 22, 2008;
117(3):
344 - 355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Casaclang-Verzosa, B. J. Gersh, and T. S.M. Tsang
Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation.
J. Am. Coll. Cardiol.,
January 1, 2008;
51(1):
1 - 11.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. G. Cosio, E. Aliot, G. L. Botto, H. Heidbuchel, C. J. Geller, P. Kirchhof, J.-C. De Haro, R. Frank, J. P. Villacastin, J. Vijgen, et al.
Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode
Europace,
January 1, 2008;
10(1):
21 - 27.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. T. Issac, H. Dokainish, and N. M. Lakkis
Role of Inflammation in Initiation and Perpetuation of Atrial Fibrillation: A Systematic Review of the Published Data
J. Am. Coll. Cardiol.,
November 20, 2007;
50(21):
2021 - 2028.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sakabe, A. Shiroshita-Takeshita, A. Maguy, C. Dumesnil, A. Nigam, T.-K. Leung, and S. Nattel
Omega-3 Polyunsaturated Fatty Acids Prevent Atrial Fibrillation Associated With Heart Failure but Not Atrial Tachycardia Remodeling
Circulation,
November 6, 2007;
116(19):
2101 - 2109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-T. Tsai, D. L. Wang, W.-P. Chen, J.-J. Hwang, C.-S. Hsieh, K.-L. Hsu, C.-D. Tseng, L.-P. Lai, Y.-Z. Tseng, F.-T. Chiang, et al.
Angiotensin II Increases Expression of {alpha}1C Subunit of L-Type Calcium Channel Through a Reactive Oxygen Species and cAMP Response Element-Binding Protein-Dependent Pathway in HL-1 Myocytes
Circ. Res.,
May 25, 2007;
100(10):
1476 - 1485.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E.W. Hemels, A. C.P. Wiesfeld, D. J. Van Veldhuisen, M. P. Van den Berg, and I. C. Van Gelder
Outcome of pharmacological rhythm control for new-onset persistent atrial fibrillation in patients with systolic heart failure: a comparison with patients with normal left ventricular function
Europace,
April 1, 2007;
9(4):
239 - 245.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Shiroshita-Takeshita, B. J.J.M. Brundel, B. Burstein, T.-K. Leung, H. Mitamura, S. Ogawa, and S. Nattel
Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure
Cardiovasc Res,
April 1, 2007;
74(1):
75 - 84.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Guler, C. Ozkara, H. Dulger, V. Kutay, M. Sahin, E. Erbilen, and H. A. Gumrukcuoglu
Do Cardiac Neuropeptides Play a Role in the Occurrence of Atrial Fibrillation After Coronary Bypass Surgery?
Ann. Thorac. Surg.,
February 1, 2007;
83(2):
532 - 537.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. C De Mello
Chronic blockade of angiotensin II AT1-receptors increased cell-to-cell communication, reduced fibrosis and improved impulse propagation in the failing heart
Journal of Renin-Angiotensin-Aldosterone System,
December 1, 2006;
7(4):
201 - 205.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. Christ, E. Wettwer, and U. Ravens
Letter by Christ et al Regarding Article, "Angiotensin II Potentiates the Slow Component of Delayed Rectifier K+ Current via the AT1 Receptor in Guinea Pig Atrial Myocytes"
Circulation,
October 31, 2006;
114(18):
e565 - e565.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Zankov, M. Omatsu-Kanbe, F. Toyoda, W.-G. Ding, H. Matsuura, T. Isono, and M. Horie
Response to Letter Regarding Article, "Angiotensin II Potentiates the Slow Component of Delayed Rectifier K+ Current via the AT1 Receptor in Guinea Pig Atrial Myocytes"
Circulation,
October 31, 2006;
114(18):
e566 - e566.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Williams
The Year in Hypertension
J. Am. Coll. Cardiol.,
October 17, 2006;
48(8):
1698 - 1711.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. W. Lee, T. H. Everett IV, D. Rahmutula, J. M. Guerra, E. Wilson, C. Ding, and J. E. Olgin
Pirfenidone Prevents the Development of a Vulnerable Substrate for Atrial Fibrillation in a Canine Model of Heart Failure
Circulation,
October 17, 2006;
114(16):
1703 - 1712.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al.
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Europace,
September 1, 2006;
8(9):
651 - 745.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Dagres, G. Karatasakis, F. Panou, G. Athanassopoulos, T. Maounis, E. Tsougos, K. Kourea, I. Malakos, D. Th. Kremastinos, and D. V. Cokkinos
Pre-treatment with Irbesartan attenuates left atrial stunning after electrical cardioversion of atrial fibrillation
Eur. Heart J.,
September 1, 2006;
27(17):
2062 - 2068.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
J. Am. Coll. Cardiol.,
August 15, 2006;
48(4):
854 - 906.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
J. Am. Coll. Cardiol.,
August 15, 2006;
48(4):
e149 - e246.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Circulation,
August 15, 2006;
114(7):
e257 - e354.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Circulation,
August 15, 2006;
114(7):
700 - 752.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/Task Force Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al.
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Eur. Heart J.,
August 2, 2006;
27(16):
1979 - 2030.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Yin, D. Dalal, Z. Liu, J. Wu, D. Liu, X. Lan, Y. Dai, L. Su, Z. Ling, Q. She, et al.
Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation
Eur. Heart J.,
August 1, 2006;
27(15):
1841 - 1846.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. P. Abhayaratna, J. B. Seward, C. P. Appleton, P. S. Douglas, J. K. Oh, A. J. Tajik, and T. S.M. Tsang
Left Atrial Size: Physiologic Determinants and Clinical Applications
J. Am. Coll. Cardiol.,
June 20, 2006;
47(12):
2357 - 2363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rotter, P. Jais, M.-C. Vergnes, P. Nurden, Y. Takahashi, P. Sanders, T. Rostock, M. Hocini, F. Sacher, and M. Haissaguerre
Decline in C-Reactive Protein After Successful Ablation of Long-Lasting Persistent Atrial Fibrillation
J. Am. Coll. Cardiol.,
March 21, 2006;
47(6):
1231 - 1233.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Zankov, M. Omatsu-Kanbe, T. Isono, F. Toyoda, W.-G. Ding, H. Matsuura, and M. Horie
Angiotensin II Potentiates the Slow Component of Delayed Rectifier K+ Current via the AT1 Receptor in Guinea Pig Atrial Myocytes
Circulation,
March 14, 2006;
113(10):
1278 - 1286.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Ehrlich, S. H. Hohnloser, and S. Nattel
Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence
Eur. Heart J.,
March 1, 2006;
27(5):
512 - 518.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Boos, R. A. Anderson, and G. Y.H. Lip
Is atrial fibrillation an inflammatory disorder?
Eur. Heart J.,
January 2, 2006;
27(2):
136 - 149.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Kalus, C. I. Coleman, and C. M. White
The Impact of Suppressing the Renin-Angiotensin System on Atrial Fibrillation
J. Clin. Pharmacol.,
January 1, 2006;
46(1):
21 - 28.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Zimetbaum
An Argument for Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation
Circulation,
June 14, 2005;
111(23):
3150 - 3156.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Gersh, T. S.M. Tsang, M. E. Barnes, and J. B. Seward
The changing epidemiology of non-valvular atrial fibrillation: the role of novel risk factors
Eur. Heart J. Suppl.,
May 1, 2005;
7(suppl_C):
C5 - C11.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Wachtell, M. Lehto, E. Gerdts, M. H. Olsen, B. Hornestam, B. Dahlof, H. Ibsen, S. Julius, S. E. Kjeldsen, L. H. Lindholm, et al.
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End point reduction in hypertension (LIFE) study
J. Am. Coll. Cardiol.,
March 1, 2005;
45(5):
712 - 719.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. G. Bourassa
Angiotensin II inhibition and prevention of atrial fibrillation and stroke
J. Am. Coll. Cardiol.,
March 1, 2005;
45(5):
720 - 721.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Kistler, N. C. Davidson, P. Sanders, S. P. Fynn, I. H. Stevenson, S. J. Spence, J. K. Vohra, P. B. Sparks, and J. M. Kalman
Absence of acute effects of angiotensin II on atrial electrophysiology in humans
J. Am. Coll. Cardiol.,
January 4, 2005;
45(1):
154 - 156.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Williams, D. T. Connelly, M. Jackson, A. Bennett, K. Albouaini, and D. M. Todd
Does treatment with ACE inhibitors or angiotensin II receptor antagonists prevent atrial fibrillation after dual chamber pacemaker implantation?
Europace,
January 1, 2005;
7(6):
554 - 559.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nattel
Antiarrhythmic drugs for atrial fibrillation: Do we need better use, better drugs or a randomized trial of ablation as primary therapy?
Can. Med. Assoc. J.,
September 28, 2004;
171(7):
752 - 753.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. D. Veenhuyzen, C. S. Simpson, and H. Abdollah
Atrial fibrillation
Can. Med. Assoc. J.,
September 28, 2004;
171(7):
755 - 760.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H Madrid, I. M. Marin, C. Escobar Cervantes, E. Bernal Morell, J. Escudero Estevez, G. Moreno, J. Rondon Parajon, Jian Peng, L. Limon, S. Nannini, et al.
Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers
Journal of Renin-Angiotensin-Aldosterone System,
September 1, 2004;
5(3):
114 - 120.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W Anne, R Willems, N Van der Merwe, F Van de Werf, H Ector, and H Heidbuchel
Atrial fibrillation after radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics
Heart,
September 1, 2004;
90(9):
1025 - 1030.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Hanna, S. Cardin, T.-K. Leung, and S. Nattel
Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure
Cardiovasc Res,
August 1, 2004;
63(2):
236 - 244.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. L'Allier, A. Ducharme, P.-F. Keller, H. Yu, M.-C. Guertin, and J.-C. Tardif
Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation
J. Am. Coll. Cardiol.,
July 7, 2004;
44(1):
159 - 164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Boldt, J. Garbade, J. F. Gummert, and S. Dhein
Reply
J. Am. Coll. Cardiol.,
June 16, 2004;
43(12):
2363 - 2364.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Cardin, D. Li, N. Thorin-Trescases, T.-K. Leung, E. Thorin, and S. Nattel
Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways
Cardiovasc Res,
November 1, 2003;
60(2):
315 - 325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. U. Klein and A. Goette
Blockade of atrial angiotensin II type 1 receptors: A novel antiarrhythmic strategy to prevent atrial fibrillation?
J. Am. Coll. Cardiol.,
June 18, 2003;
41(12):
2205 - 2206.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Savelieva and A. John Camm
Atrial fibrillation and heart failure: natural history and pharmacological treatment
Europace,
January 1, 2003;
5(s1):
S5 - S19.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
Top
Abstract
Methods